|Bid||41.50 x 1200|
|Ask||53.22 x 1300|
|Day's range||49.01 - 51.66|
|52-week range||36.16 - 92.57|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||76.00|
Shares of life sciences company Quanterix (NASDAQ: QTRX) are up 14% as of 11:30 a.m. EDT today after the Food and Drug Administration granted breakthrough status to its blood test for a biomarker of Alzheimer's disease. Tau is a protein that stabilizes microtubules in the neurons of the central nervous system. In Alzheimer's disease, tau detaches from the microtubules and tangles.
BILLERICA, Mass., October 11, 2021--Quanterix Corporation granted Breakthrough Device designation from FDA for its blood-based pTau-181 assay for Alzheimer's Disease.
BILLERICA, Mass., September 20, 2021--Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories